Patents by Inventor Ho Hong Hai Vo

Ho Hong Hai Vo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Live recombinant measles-M2 virus—its use in eliciting immunity against influenza viruses
    Patent number: 11160858
    Abstract: The invention relates to an active ingredient which is a live attenuated recombinant measles virus expressing influenza A virus antigen(s) and to its use in the elicitation of immunity, in particular protective immunity and advantageously broad-spectrum protective immunity against influenza A virus. In particular, the influenza A virus is selected among epidemic seasonal viruses and/or endemic viruses circulating in the human population and advantageously encompasses a pandemic virus such as H1N1v.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 2, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Nicolas Robert Xavier Escriou, Frederic Tangy, Ho Hong Hai Vo
  • LIVE RECOMBINANT MEASLES-M2 VIRUS - ITS USE IN ELICITING IMMUNITY AGAINST INFLUENZA VIRUSES
    Publication number: 20180228888
    Abstract: The invention relates to an active ingredient which is a live attenuated recombinant measles virus expressing influenza A virus antigen(s) and to its use in the elicitation of immunity, in particular protective immunity and advantageously broad-spectrum protective immunity against influenza A virus. In particular, the influenza A virus is selected among epidemic seasonal viruses and/or endemic viruses circulating in the human population and advantageously encompasses a pandemic virus such as H1N1v.
    Type: Application
    Filed: June 10, 2016
    Publication date: August 16, 2018
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Nicolas Robert Xavier ESCRIOU, Frederic TANGY, Ho Hong Hai VO
  • Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
    Patent number: 9011939
    Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: April 21, 2015
    Assignees: Elicityl, Centre National de la Recherche Scientifique, Insititut National de la Sante et de la Recherche Medicale—I.N.S.E.R.M., Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA)
    Inventors: Bruno Lina, Olivier Ferraris, Ho Hong Hai Vo, François-Loïc Cosset, Judit Szecsi, Alain Heyraud, Hugues Lortat-Jacob, Julia Bartoli, Rabia Sadir, Thierry Livache, Benoît Darblade, Stéphane Havet, Silvère Bonnet
  • SULPHATED ARABINOGALACTANS, APIOGALACTURONANS AND SULPHATED HETEROGLYCANS FOR TREATING DISEASES CAUSED BY THE INFLUENZA VIRUS
    Publication number: 20140023675
    Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.
    Type: Application
    Filed: January 3, 2012
    Publication date: January 23, 2014
    Applicants: Elicityl, Commissariat A L'Energie Atomique Et Aux Energies Alternatives (CEA), Institut National De La Sante Et De La Recherche Medicale - I.N.S.E.R.M., Centre National De La Recherche Scientifique
    Inventors: Bruno Lina, Olivier Ferraris, Ho Hong Hai Vo, Francois-Loic Cosset, Judit Szecsi, Alain Heyraud, Hugues Lortat-Jacob, Julia Bartoli, Rabia Sadir, Thierry Livache, Benoit Darblade, Stephane Havet, Silvére Bonnet